-
The Longtail Re deal buys the specialty insurer time to secure its future, or an exit for shareholders. -
“Hammer letters” are going around, and insurers are struggling to coordinate on claims handling.
-
The play would shrink the check size required, improve alignment, and buy time to prepare for a future IPO or sale.
-
The number of nuclear verdicts rebounded to pre-pandemic levels by 2022, USCC data shows.
-
The firm’s underwriting performance is hard to piece together from the limited available data.
-
Floir has sent more than 20 letters to Florida executives for potential violation of Statute 624.4073.
-
Recent contingency losses reflect a willingness of the market to go looking for premiums.
-
The firm will no longer have to compete with one hand tied behind its back.
-
From here on out, insurers will likely have to rely on the strength of their individual stories.
-
Avoiding an antitrust fight aids execution, but creates uncomfortable optics around the multiple paid.
-
Flexpoint secured a higher sum-of-the-parts valuation by facilitating the break-up.
-
The agreement from Fleming to honour original terms still leaves it open to long-term damage.
